NCT06147570 - A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions

Nonsmall Cell Lung Cancer

Interventions

DRUG

HS-10365 capsules

HS-10365 will be administered orally twice daily until the occurrence of disease progression, unacceptable adverse events, withdrawal of consent, death or the end of the study.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Chest Hospital, Shanghai